The fourth component, GHK-Cu, will be voted on in a subsequent February 2027 meeting HHS has announced that GHK-Cu is expected to return to Category 1 (after being moved to Category 2 in September 2023), which would restore compounding access for injectable formulations. The recommendations of the PCAC are non-binding but noteworthy
Some people may start with semaglutide, because it has been available longer and may have better insurance coverage
Unless someone is engaging in prolonged physical activity of over 60 minutes per day at vigorous intensity or in high heat, has a medical condition requiring electrolyte replacement, or has been advised by a healthcare professional, daily electrolyte supplementation is unnecessary (AHA, 2024)
Patients who reached the 2.4 mg maintenance dose and remained on it reported marked improvement in nausea by weeks 20 to 24, approximately 4 to 8 weeks after completing the titration schedule [1]
"Triple-Hormone-Receptor Agonist Retatrutide for Obesity A Phase 2 Trial." N Engl J Med